Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

A kinase-independent role for CDK8 in BCR-ABL1+ leukemia.

Menzl I, Zhang T, Berger-Becvar A, Grausenburger R, Heller G, Prchal-Murphy M, Edlinger L, Knab VM, Uras IZ, Grundschober E, Bauer K, Roth M, Skucha A, Liu Y, Hatcher JM, Liang Y, Kwiatkowski NP, Fux D, Hoelbl-Kovacic A, Kubicek S, Melo JV, Valent P, Weichhart T, Grebien F, Zuber J, Gray NS, Sexl V.

Nat Commun. 2019 Oct 18;10(1):4741. doi: 10.1038/s41467-019-12656-x.

PMID:
31628323
2.

Human STAT5b mutation causes dysregulated human natural killer cell maturation and impaired lytic function.

Vargas-Hernández A, Witalisz-Siepracka A, Prchal-Murphy M, Klein K, Mahapatra S, Al-Herz W, Mace EM, Carisey AF, Orange JS, Sexl V, Forbes LR.

J Allergy Clin Immunol. 2019 Oct 7. pii: S0091-6749(19)31252-7. doi: 10.1016/j.jaci.2019.09.016. [Epub ahead of print]

PMID:
31600547
3.

CDK8-Novel Therapeutic Opportunities.

Menzl I, Witalisz-Siepracka A, Sexl V.

Pharmaceuticals (Basel). 2019 Jun 19;12(2). pii: E92. doi: 10.3390/ph12020092. Review.

4.

High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.

Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R.

Haematologica. 2019 May 23. pii: haematol.2019.216986. doi: 10.3324/haematol.2019.216986. [Epub ahead of print]

5.

STAT5BN642H drives transformation of NKT cells: a novel mouse model for CD56+ T-LGL leukemia.

Klein K, Witalisz-Siepracka A, Maurer B, Prinz D, Heller G, Leidenfrost N, Prchal-Murphy M, Suske T, Moriggl R, Sexl V.

Leukemia. 2019 Sep;33(9):2336-2340. doi: 10.1038/s41375-019-0471-3. Epub 2019 Apr 9. No abstract available.

6.

Shp-2 is critical for ERK and metabolic engagement downstream of IL-15 receptor in NK cells.

Niogret C, Miah SMS, Rota G, Fonta NP, Wang H, Held W, Birchmeier W, Sexl V, Yang W, Vivier E, Ho PC, Brossay L, Guarda G.

Nat Commun. 2019 Mar 29;10(1):1444. doi: 10.1038/s41467-019-09431-3.

7.

Myeloid Cells Restrict MCMV and Drive Stress-Induced Extramedullary Hematopoiesis through STAT1.

Gawish R, Bulat T, Biaggio M, Lassnig C, Bago-Horvath Z, Macho-Maschler S, Poelzl A, Simonović N, Prchal-Murphy M, Rom R, Amenitsch L, Ferrarese L, Kornhoff J, Lederer T, Svinka J, Eferl R, Bosmann M, Kalinke U, Stoiber D, Sexl V, Krmpotić A, Jonjić S, Müller M, Strobl B.

Cell Rep. 2019 Feb 26;26(9):2394-2406.e5. doi: 10.1016/j.celrep.2019.02.017.

8.

NK Cells Require Cell-Extrinsic and -Intrinsic TYK2 for Full Functionality in Tumor Surveillance and Antibacterial Immunity.

Simonović N, Witalisz-Siepracka A, Meissl K, Lassnig C, Reichart U, Kolbe T, Farlik M, Bock C, Sexl V, Müller M, Strobl B.

J Immunol. 2019 Mar 15;202(6):1724-1734. doi: 10.4049/jimmunol.1701649. Epub 2019 Feb 4.

9.

Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.

Kollmann S, Grundschober E, Maurer B, Warsch W, Grausenburger R, Edlinger L, Huuhtanen J, Lagger S, Hennighausen L, Valent P, Decker T, Strobl B, Mueller M, Mustjoki S, Hoelbl-Kovacic A, Sexl V.

Leukemia. 2019 Jul;33(7):1583-1597. doi: 10.1038/s41375-018-0369-5. Epub 2019 Jan 24.

10.

Loss of JAK1 Drives Innate Immune Deficiency.

Witalisz-Siepracka A, Klein K, Prinz D, Leidenfrost N, Schabbauer G, Dohnal A, Sexl V.

Front Immunol. 2019 Jan 8;9:3108. doi: 10.3389/fimmu.2018.03108. eCollection 2018.

11.

CDK6 coordinates JAK2 V617F mutant MPN via NF-κB and apoptotic networks.

Uras IZ, Maurer B, Nivarthi H, Jodl P, Kollmann K, Prchal-Murphy M, Milosevic Feenstra JD, Zojer M, Lagger S, Grausenburger R, Grabner B, Holly R, Kavirayani A, Bock C, Gisslinger H, Valent P, Kralovics R, Sexl V.

Blood. 2019 Apr 11;133(15):1677-1690. doi: 10.1182/blood-2018-08-872648. Epub 2019 Jan 11.

12.

Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib.

Uras IZ, Maurer B, Nebenfuehr S, Zojer M, Valent P, Sexl V.

Int J Mol Sci. 2018 Dec 11;19(12). pii: E3987. doi: 10.3390/ijms19123987.

13.

The RNA helicase DDX3X is an essential mediator of innate antimicrobial immunity.

Szappanos D, Tschismarov R, Perlot T, Westermayer S, Fischer K, Platanitis E, Kallinger F, Novatchkova M, Lassnig C, Müller M, Sexl V, Bennett KL, Foong-Sobis M, Penninger JM, Decker T.

PLoS Pathog. 2018 Nov 26;14(11):e1007397. doi: 10.1371/journal.ppat.1007397. eCollection 2018 Nov.

14.

T-bet controls intestinal mucosa immune responses via repression of type 2 innate lymphoid cell function.

Garrido-Mesa N, Schroeder JH, Stolarczyk E, Gallagher AL, Lo JW, Bailey C, Campbell L, Sexl V, MacDonald TT, Howard JK, Grencis RK, Powell N, Lord GM.

Mucosal Immunol. 2019 Jan;12(1):51-63. doi: 10.1038/s41385-018-0092-6. Epub 2018 Oct 24.

15.

Cdk6: At the interface of Rb and p53.

Nebenfuehr S, Bellutti F, Sexl V.

Mol Cell Oncol. 2018 Sep 5;5(5):e1511206. doi: 10.1080/23723556.2018.1511206. eCollection 2018.

16.

NK cell receptor NKG2D sets activation threshold for the NCR1 receptor early in NK cell development.

Jelenčić V, Šestan M, Kavazović I, Lenartić M, Marinović S, Holmes TD, Prchal-Murphy M, Lisnić B, Sexl V, Bryceson YT, Wensveen FM, Polić B.

Nat Immunol. 2018 Oct;19(10):1083-1092. doi: 10.1038/s41590-018-0209-9. Epub 2018 Sep 17.

17.

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H, Sexl V.

Blood. 2018 Aug 16;132(7):694-706. doi: 10.1182/blood-2017-10-810739. Epub 2018 Jun 14. Erratum in: Blood. 2019 Feb 14;133(7):768.

PMID:
29907599
18.

CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.

Bellutti F, Tigan AS, Nebenfuehr S, Dolezal M, Zojer M, Grausenburger R, Hartenberger S, Kollmann S, Doma E, Prchal-Murphy M, Uras IZ, Höllein A, Neuberg DS, Ebert BL, Ringler A, Mueller AC, Loizou JI, Hinds PW, Vogl C, Heller G, Kubicek S, Zuber J, Malumbres M, Farlik M, Villunger A, Kollmann K, Sexl V.

Cancer Discov. 2018 Jul;8(7):884-897. doi: 10.1158/2159-8290.CD-17-0912. Epub 2018 Jun 13.

19.

An ERK-Dependent Feedback Mechanism Prevents Hematopoietic Stem Cell Exhaustion.

Baumgartner C, Toifl S, Farlik M, Halbritter F, Scheicher R, Fischer I, Sexl V, Bock C, Baccarini M.

Cell Stem Cell. 2018 Jun 1;22(6):879-892.e6. doi: 10.1016/j.stem.2018.05.003. Epub 2018 May 24.

20.

Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.

Blatt K, Menzl I, Eisenwort G, Cerny-Reiterer S, Herrmann H, Herndlhofer S, Stefanzl G, Sadovnik I, Berger D, Keller A, Hauswirth A, Hoermann G, Willmann M, Rülicke T, Sill H, Sperr WR, Mannhalter C, Melo JV, Jäger U, Sexl V, Valent P.

Neoplasia. 2018 Jun;20(6):632-642. doi: 10.1016/j.neo.2018.04.004. Epub 2018 May 15.

21.

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis.

Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O.

Immunity. 2018 Feb 20;48(2):396-398. doi: 10.1016/j.immuni.2018.01.010. No abstract available.

22.

DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation.

Xiao Q, Wu J, Wang WJ, Chen S, Zheng Y, Yu X, Meeth K, Sahraei M, Bothwell ALM, Chen L, Bosenberg M, Chen J, Sexl V, Sun L, Li L, Tang W, Wu D.

Nat Med. 2018 Mar;24(3):262-270. doi: 10.1038/nm.4496. Epub 2018 Feb 12.

23.

NK Cell-Specific CDK8 Deletion Enhances Antitumor Responses.

Witalisz-Siepracka A, Gotthardt D, Prchal-Murphy M, Didara Z, Menzl I, Prinz D, Edlinger L, Putz EM, Sexl V.

Cancer Immunol Res. 2018 Apr;6(4):458-466. doi: 10.1158/2326-6066.CIR-17-0183. Epub 2018 Jan 31.

24.

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis.

Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O.

Immunity. 2018 Jan 16;48(1):107-119.e4. doi: 10.1016/j.immuni.2017.12.007. Epub 2018 Jan 9. Erratum in: Immunity. 2018 Feb 20;48(2):396-398.

25.

STAT5BN642H is a driver mutation for T cell neoplasia.

Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, Nivarthi H, Boersma A, Kolbe T, Elabd M, Halbritter F, Pencik J, Kazemi Z, Grebien F, Hengstschläger M, Kenner L, Kubicek S, Farlik M, Bock C, Valent P, Müller M, Rülicke T, Sexl V, Moriggl R.

J Clin Invest. 2018 Jan 2;128(1):387-401. doi: 10.1172/JCI94509. Epub 2017 Dec 4.

26.

Blocking antibodies induced by allergen-specific immunotherapy ameliorate allergic airway disease in a human/mouse chimeric model.

Vizzardelli C, Gindl M, Roos S, Möbs C, Nagl B, Zimmann F, Sexl V, Kenner L, Neunkirchner A, Zlabinger GJ, Pickl WF, Pfützner W, Bohle B.

Allergy. 2018 Apr;73(4):851-861. doi: 10.1111/all.13363. Epub 2017 Dec 22.

PMID:
29159964
27.

Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis.

Krzywinska E, Kantari-Mimoun C, Kerdiles Y, Sobecki M, Isagawa T, Gotthardt D, Castells M, Haubold J, Millien C, Viel T, Tavitian B, Takeda N, Fandrey J, Vivier E, Sexl V, Stockmann C.

Nat Commun. 2017 Nov 17;8(1):1597. doi: 10.1038/s41467-017-01599-w.

28.

Increased NK cell immunity in a transgenic mouse model of NKp46 overexpression.

Glasner A, Isaacson B, Viukov S, Neuman T, Friedman N, Mandelboim M, Sexl V, Hanna JH, Mandelboim O.

Sci Rep. 2017 Oct 12;7(1):13090. doi: 10.1038/s41598-017-12998-w.

29.

p27 in FLT3-driven acute myeloid leukemia: many roads lead to ruin.

Uras IZ, Bellutti F, Sexl V.

Haematologica. 2017 Aug;102(8):1299-1301. doi: 10.3324/haematol.2017.171819. No abstract available.

30.

Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells.

Streicher C, Heyny A, Andrukhova O, Haigl B, Slavic S, Schüler C, Kollmann K, Kantner I, Sexl V, Kleiter M, Hofbauer LC, Kostenuik PJ, Erben RG.

Sci Rep. 2017 Jul 25;7(1):6460. doi: 10.1038/s41598-017-06614-0.

31.

Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1.

Edlinger L, Berger-Becvar A, Menzl I, Hoermann G, Greiner G, Grundschober E, Bago-Horvath Z, Al-Zoughbi W, Hoefler G, Brostjan C, Gille L, Moriggl R, Spittler A, Sexl V, Hoelbl-Kovacic A.

Br J Haematol. 2017 Oct;179(2):229-241. doi: 10.1111/bjh.14833. Epub 2017 Jul 14.

32.

IL-6/Stat3-Dependent Induction of a Distinct, Obesity-Associated NK Cell Subpopulation Deteriorates Energy and Glucose Homeostasis.

Theurich S, Tsaousidou E, Hanssen R, Lempradl AM, Mauer J, Timper K, Schilbach K, Folz-Donahue K, Heilinger C, Sexl V, Pospisilik JA, Wunderlich FT, Brüning JC.

Cell Metab. 2017 Jul 5;26(1):171-184.e6. doi: 10.1016/j.cmet.2017.05.018.

33.

It is a differentiation game: STAT5 in a new role.

Maurer B, Farlik M, Sexl V.

Cell Death Differ. 2017 Jun;24(6):953-954. doi: 10.1038/cdd.2017.71. Epub 2017 May 12. No abstract available.

34.

Cdk6 contributes to cytoskeletal stability in erythroid cells.

Uras IZ, Scheicher RM, Kollmann K, Glösmann M, Prchal-Murphy M, Tigan AS, Fux DA, Altamura S, Neves J, Muckenthaler MU, Bennett KL, Kubicek S, Hinds PW, von Lindern M, Sexl V.

Haematologica. 2017 Jun;102(6):995-1005. doi: 10.3324/haematol.2016.159947. Epub 2017 Mar 2.

35.

STATs in NK-Cells: The Good, the Bad, and the Ugly.

Gotthardt D, Sexl V.

Front Immunol. 2017 Jan 18;7:694. doi: 10.3389/fimmu.2016.00694. eCollection 2016. Review.

36.

Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression.

Linke M, Pham HT, Katholnig K, Schnöller T, Miller A, Demel F, Schütz B, Rosner M, Kovacic B, Sukhbaatar N, Niederreiter B, Blüml S, Kuess P, Sexl V, Müller M, Mikula M, Weckwerth W, Haschemi A, Susani M, Hengstschläger M, Gambello MJ, Weichhart T.

Nat Immunol. 2017 Mar;18(3):293-302. doi: 10.1038/ni.3655. Epub 2017 Jan 16.

37.

NKG2D Promotes B1a Cell Development and Protection against Bacterial Infection.

Lenartić M, Jelenčić V, Zafirova B, Ožanič M, Marečić V, Jurković S, Sexl V, Šantić M, Wensveen FM, Polić B.

J Immunol. 2017 Feb 15;198(4):1531-1542. doi: 10.4049/jimmunol.1600461. Epub 2017 Jan 13.

38.

O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies.

Freund P, Kerenyi MA, Hager M, Wagner T, Wingelhofer B, Pham HTT, Elabd M, Han X, Valent P, Gouilleux F, Sexl V, Krämer OH, Groner B, Moriggl R.

Leukemia. 2017 Oct;31(10):2132-2142. doi: 10.1038/leu.2017.4. Epub 2017 Jan 11.

39.

CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.

Greiner G, Witzeneder N, Berger A, Schmetterer K, Eisenwort G, Schiefer AI, Roos S, Popow-Kraupp T, Müllauer L, Zuber J, Sexl V, Kenner L, Sperr WR, Valent P, Mayerhofer M, Hoermann G.

Blood. 2017 Jan 19;129(3):371-382. doi: 10.1182/blood-2016-09-739003. Epub 2016 Nov 16.

PMID:
27856463
40.

Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity.

Putz EM, Majoros A, Gotthardt D, Prchal-Murphy M, Zebedin-Brandl EM, Fux DA, Schlattl A, Schreiber RD, Carotta S, Müller M, Gerner C, Decker T, Sexl V.

Oncoimmunology. 2016 May 19;5(9):e1186314. eCollection 2016.

41.

MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.

Sochalska M, Schuler F, Weiss JG, Prchal-Murphy M, Sexl V, Villunger A.

Oncogene. 2017 Apr;36(15):2066-2073. doi: 10.1038/onc.2016.362. Epub 2016 Oct 3.

42.

Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia.

Klose R, Krzywinska E, Castells M, Gotthardt D, Putz EM, Kantari-Mimoun C, Chikdene N, Meinecke AK, Schrödter K, Helfrich I, Fandrey J, Sexl V, Stockmann C.

Nat Commun. 2016 Aug 19;7:12528. doi: 10.1038/ncomms12528.

43.

A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis.

Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott RG, Schäfer M, Fajmann S, Schlederer M, Schiefer AI, Reichart U, Mayerhofer M, Hoeller C, Zöchbauer-Müller S, Kerjaschki D, Bock C, Kenner L, Hoefler G, Freissmuth M, Green AR, Moriggl R, Busslinger M, Malumbres M, Sexl V.

Cancer Cell. 2016 Aug 8;30(2):359-360. doi: 10.1016/j.ccell.2016.07.003. Epub 2016 Aug 8. No abstract available.

44.

Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models.

Bottos A, Gotthardt D, Gill JW, Gattelli A, Frei A, Tzankov A, Sexl V, Wodnar-Filipowicz A, Hynes NE.

Nat Commun. 2016 Jul 13;7:12258. doi: 10.1038/ncomms12258.

45.

Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.

Uras IZ, Walter GJ, Scheicher R, Bellutti F, Prchal-Murphy M, Tigan AS, Valent P, Heidel FH, Kubicek S, Scholl C, Fröhling S, Sexl V.

Blood. 2016 Jun 9;127(23):2890-902. doi: 10.1182/blood-2015-11-683581. Epub 2016 Apr 20.

46.

Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation.

Kazemi Z, Bergmayr C, Prchal-Murphy M, Javaheri T, Themanns M, Pham HT, Strohmaier W, Sexl V, Freissmuth M, Zebedin-Brandl E.

Mol Pharmacol. 2016 Jun;89(6):630-44. doi: 10.1124/mol.116.103267. Epub 2016 Mar 17.

47.

Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice.

Bauer E, Schlederer M, Scheicher R, Horvath J, Aigner P, Schiefer AI, Kain R, Regele H, Hoermann G, Steiner G, Kenner L, Sexl V, Villunger A, Moriggl R, Stoiber D.

Oncotarget. 2016 Mar 15;7(11):12191-205. doi: 10.18632/oncotarget.7687.

48.

Response to interferons and antibacterial innate immunity in the absence of tyrosine-phosphorylated STAT1.

Majoros A, Platanitis E, Szappanos D, Cheon H, Vogl C, Shukla P, Stark GR, Sexl V, Schreiber R, Schindler C, Müller M, Decker T.

EMBO Rep. 2016 Mar;17(3):367-82. doi: 10.15252/embr.201540726. Epub 2016 Feb 12.

49.

STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion.

Gotthardt D, Putz EM, Grundschober E, Prchal-Murphy M, Straka E, Kudweis P, Heller G, Bago-Horvath Z, Witalisz-Siepracka A, Cumaraswamy AA, Gunning PT, Strobl B, Müller M, Moriggl R, Stockmann C, Sexl V.

Cancer Discov. 2016 Apr;6(4):414-29. doi: 10.1158/2159-8290.CD-15-0732. Epub 2016 Feb 12.

50.

Antigen receptor-mediated depletion of FOXP3 in induced regulatory T-lymphocytes via PTPN2 and FOXO1.

Bothur E, Raifer H, Haftmann C, Stittrich AB, Brüstle A, Brenner D, Bollig N, Bieringer M, Kang CH, Reinhard K, Camara B, Huber M, Visekruna A, Steinhoff U, Repenning A, Bauer UM, Sexl V, Radbruch A, Sparwasser T, Mashreghi MF, Wah Mak T, Lohoff M.

Nat Commun. 2015 Oct 13;6:8576. doi: 10.1038/ncomms9576.

Supplemental Content

Support Center